Introduction
============

Plantar fasciitis is the most common cause of interior heel pain and affects approximately 10% of the general population.[@b1-jpr-10-1933] It is characterized by heel pain and tenderness centered on the medial tubercle of the calcaneus on weight bearing, especially immediately after rest, such as getting out of bed in the morning.[@b2-jpr-10-1933] Although plantar fasciitis is regarded as a self-limiting disease,[@b3-jpr-10-1933],[@b4-jpr-10-1933] it can take up to months or even years to recover.[@b5-jpr-10-1933]

The etiology of plantar fasciitis is still unclear. Simons et al[@b6-jpr-10-1933] proposed that the presence of myofascial trigger points (MTrPs) within the plantar intrinsic foot musculature and muscles proximal to the foot might play an important role in plantar heel pain. MTrPs have been defined as hyperirritable points located in taut bands of skeletal muscle or fascia.[@b7-jpr-10-1933] The spot is tender when pressed and can give rise to characteristic referred pain, motor dysfunction, and autonomic phenomena.[@b7-jpr-10-1933]

Current conventional treatments include rest, administration of nonsteroidal anti-inflammatory drugs, foot taping, physical therapy, stretch exercise, and steroid injection.[@b8-jpr-10-1933] Steroid injection is one of the most popular methods used in this condition, and it has been reported to be effective in the short term;[@b8-jpr-10-1933] however, it may lead to serious adverse events such as a recognized risk of subsequent plantar fascia rupture.[@b9-jpr-10-1933],[@b10-jpr-10-1933] Dry needling and acupuncture are increasingly being used to treat heel pain, as well as many other musculoskeletal pain conditions.[@b11-jpr-10-1933]

Dry needling and acupuncture are alternative and less-invasive procedures, which stimulate the MTrPs.[@b12-jpr-10-1933],[@b13-jpr-10-1933] It has been reported that dry needling can alter the biochemical environment surrounding an MTrP and reduce spontaneous electrical activity within the MTrP regions of skeletal muscle.[@b14-jpr-10-1933],[@b15-jpr-10-1933] Moreover, this method is safe with minimal side effects when treating chronic pains. Several studies have assessed the effects of MTrP dry needling in the treatment of plantar heel pain.[@b3-jpr-10-1933],[@b12-jpr-10-1933],[@b13-jpr-10-1933] However, their results remain controversial. Therefore, we conducted this meta-analysis to assess the effects of MTrP dry needling in patients with heel pain due to plantar fasciitis.

Materials and methods
=====================

Literature search
-----------------

We performed this meta-analysis in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement guidelines.[@b16-jpr-10-1933] Two independent investigators conducted a comprehensive literature review. PubMed, Embase, Web of Science, SinoMed (Chinese BioMedical Literature Service System, People's Republic of China), and CNKI (National Knowledge Infrastructure, People's Republic of China) were systematically searched to identify relevant articles up to March 12, 2017. The following structured search strategies were used: (Plantar\[All Fields\] AND ("heel"\[MeSH Terms\] OR "heel"\[All Fields\]) AND ("pain"\[MeSH Terms\] OR "pain"\[All Fields\])) AND (myofascial\[All Fields\] AND ("trigger points"\[MeSH Terms\] OR ("trigger"\[All Fields\] AND "points"\[All Fields\]) OR "trigger points"\[All Fields\])) AND ((dry\[All Fields\] AND needling\[All Fields\]) OR ("acupuncture"\[MeSH Terms\] OR "acupuncture"\[All Fields\] OR "acupuncture therapy"\[MeSH Terms\] OR ("acupuncture"\[All Fields\] AND "therapy"\[All Fields\]) OR "acupuncture therapy"\[All Fields\])). The search was limited to human subjects, and no language restriction was imposed. In addition, we also manually searched the reference lists of the included studies and previous reviews until no potentially eligible studies could be identified.

Study selection
---------------

We included full-text publications when the following inclusion criteria were met: 1) study design: randomized controlled trial (RCT); 2) population: adult patients aged 18 years or older who were diagnosed with plantar heel pain (plantar fasciitis); 3) intervention: dry needing/acupuncture of the MTrPs; 4) control: placebo or other treatment; and 5) outcome measure: changes in visual analog scale (VAS) score, success rate for pain, and adverse events. Studies were excluded if the needles in the active treatment group were inserted superficially over the site of an MTrP or into traditional acupuncture points. The rationale for this decision was based on the fact that the relationship between traditional acupuncture points and MTrP is unclear.[@b17-jpr-10-1933]

Data extraction
---------------

We used a data extraction sheet to extract data from the included studies. The following information was extracted: first author's name, year of publication, country, number of patients in each group, patient characteristics, methods used for randomization, concealment, blinding, and the main outcomes (changes in the VAS score, success rate for pain, and incidence of adverse events). We also contacted the corresponding author for further information when the data needed clarification or were not presented in their studies.

Risk of bias assessment and grading quality of evidence
-------------------------------------------------------

We used the method recommended by the Cochrane Collaboration[@b18-jpr-10-1933] to assess the risk of bias in RCTs. This method consists of the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other bias.[@b19-jpr-10-1933] Each study was classified as of "high", "unclear", or "low" risk of bias according to these domains.[@b19-jpr-10-1933]

The quality of evidence for outcome measures was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.[@b20-jpr-10-1933] The quality of each outcome was classified as very low, low, moderate, or high.[@b20-jpr-10-1933] A summary table was constructed using the GRADEprofiler (GRADEpro, version 3.6; <http://www.gradeworkinggroup.org/>).

Statistical analysis
--------------------

The current meta-analysis was performed using Stata 12.0 (Stata Corporation, College Station, TX, USA). For continuous outcomes, they were expressed as weighted mean difference (WMD) with 95% CIs; for dichotomous outcomes, they were expressed as risk ratio (RR) with 95% CI. Before the data were pooled, we used the Cochrane Q chi-square test and *I*^2^ statistic to test the heterogeneity across studies, in which *P*-value \<0.1 or *I*^2^\>50% were considered to be significant.[@b21-jpr-10-1933] A random-effects model (DerSimonian--Laird method)[@b22-jpr-10-1933] was used to pool data when significant heterogeneity was identified; otherwise, a fixed-effects model (Mantel--Haenszel method)[@b23-jpr-10-1933] was used. We also conducted sensitivity analysis and subgroup analysis (based on different durations) to explore the potential sources of heterogeneity whenever significant heterogeneity was present. The presence of publication bias was assessed by the Begg[@b24-jpr-10-1933] and Egger's tests.[@b25-jpr-10-1933] A two-tailed *P--*value \<0.05 was considered statistically significant, except where a certain *P*-value had been specified.

Results
=======

Search results
--------------

The initial search yielded 1,941 publications, of which 1,546 were excluded because of presence of duplicate records. Then, 385 were excluded because of various reasons (reviews, case series, non-RCTs, or not relevant with our topics) after the review of titles/abstract. Ten potential studies were identified for full-text information, but three were excluded because two were single-arm studies,[@b26-jpr-10-1933],[@b27-jpr-10-1933] and one was a protocol article.[@b11-jpr-10-1933] Finally, seven RCTs met the inclusion criteria and were included in this meta-analysis ([Figure 1](#f1-jpr-10-1933){ref-type="fig"}).[@b28-jpr-10-1933]--[@b34-jpr-10-1933]

Study characteristics
---------------------

The main characteristics of the included studies are shown in [Table 1](#t1-jpr-10-1933){ref-type="table"}. These studies were published between 2011 and 2017. The number of participants ranged from 20 to 108. Of the seven studies, four were conducted in People's Republic of China,,[@b29-jpr-10-1933],[@b31-jpr-10-1933],[@b33-jpr-10-1933],[@b34-jpr-10-1933] one in Australia,[@b28-jpr-10-1933] one in Iran,[@b30-jpr-10-1933] and one in Thailand.[@b32-jpr-10-1933] Among the seven RCTs, five were published in English language,[@b28-jpr-10-1933]--[@b32-jpr-10-1933] and two in Chinese language.[@b33-jpr-10-1933],[@b34-jpr-10-1933] The diagnosis of MTrP varied greatly among the included studies. Some used the palpation of "tender spot in a taut band" and "local twitch response",[@b29-jpr-10-1933],[@b33-jpr-10-1933],[@b34-jpr-10-1933] while some others added "patient recognition of pain on sustained compression over the tender point" as a confirmatory finding.[@b28-jpr-10-1933],[@b30-jpr-10-1933]--[@b32-jpr-10-1933] All RCTs used a VAS to measure the intensity of pain. The success for pain was defined as a minimum decrease of 50% in VAS scores.

Risk of bias and evidence of quality
------------------------------------

The details of risk bias are presented in [Figure 2](#f2-jpr-10-1933){ref-type="fig"}. Overall, two RCTs[@b31-jpr-10-1933],[@b32-jpr-10-1933] were regarded as being at low risk of bias, three[@b29-jpr-10-1933],[@b33-jpr-10-1933],[@b34-jpr-10-1933] at unclear risk of bias, and two[@b28-jpr-10-1933],[@b30-jpr-10-1933] at high risk of bias. The main reasons for the two RCTs being at high risk of bias were that the studies were not blinded to the participants or outcome assessors. The main reasons for the three RCTs being at unclear risk of bias were that they did not report the methods used for randomized sequence or allocation sequence concealment adequately.

The GRADE evidence profiles for these outcomes are shown in [Table 2](#t2-jpr-10-1933){ref-type="table"}. The quality of evidence was moderate for change in VAS scores and success rate for pain, but low for adverse events.

Meta-analysis of outcome measures
---------------------------------

All the studies reported the data on changes in VAS scores.[@b28-jpr-10-1933]--[@b34-jpr-10-1933] The aggregated results of these studies showed that MTrP needling was associated with a significantly greater reduction in VAS score (WMD =−15.50, 95% CI: −19.48, −11.53; *P*\<0.001) ([Figure 3](#f3-jpr-10-1933){ref-type="fig"}). There was moderate heterogeneity among the included studies (*I*^2^=56.8%, *P*=0.013). Subgroup analysis was conducted based on different durations. At 1, 6, and 12 months, MTrP needling significantly reduced VAS score (at 1 month: WMD =−15.04, 95% CI: −20.14, −9.94; *P*\<0.001; at 6 months: WMD =−18.20, 95% CI: −26.95, −9.45; *P*\<0.001; at 12 months: WMD =−24.10, 95% CI: −35.45, −12.75; *P*\<0.001).

In the MTrP needling group, VAS scores for morning pain and active pain were significantly decreased compared with control (morning pain: WMD =−42.46, 95% CI: −58.79, −26.12; *P*\<0.001; activity pain: WMD =−38.92, 95% CI: −55.16, −22.67; *P*\<0.001).

Three studies reported the success rate for pain.[@b32-jpr-10-1933]--[@b34-jpr-10-1933] The aggregated results of these studies suggested that MTrP needling was associated with a success rate for treatment of pain comparable with that of the control (RR =1.15, 95% CI: 0.87, 1.51; *P*=0.320) ([Figure 4](#f4-jpr-10-1933){ref-type="fig"}).

Three studies reported the adverse events.[@b28-jpr-10-1933],[@b29-jpr-10-1933],[@b32-jpr-10-1933] These immediate adverse events were related to needle site pain and were transient in nature. The aggregated results of these studies suggested that the incidence of adverse events was similar between the MTrP needling and control groups (RR =1.89, 95% CI: 0.38, 9.39; *P*=0.438).

Publication bias
----------------

We performed the assessment of publication bias for VAS score using Egger's and Begg's tests. The results showed that there was no potential publication bias among the included studies (Egger's test: *P*=0.169; Begg's test: *P*=0.283) ([Figure 5](#f5-jpr-10-1933){ref-type="fig"}).

Discussion
==========

The aim of this meta-analysis was to assess the effects of MTrP needling in the treatment of patients with plantar heel pain. The pooled estimates of all seven included trials using a random-effects model showed that MTrP needling significantly reduced the VAS score and was associated with a similar success rate for pain compared with control. Moreover, the improvements of pain relief were maintained throughout the 12-month follow-up, which indicated that this treatment offered long-term effectiveness. The incidence of adverse events was comparable between MTrP needling and control groups.

There have been three similar systematic reviews or meta-analyses[@b35-jpr-10-1933]--[@b37-jpr-10-1933] that should be noted. Tough et al[@b35-jpr-10-1933] conducted a systematic review and meta-analysis of seven RCTs. Among these studies, four investigated patients with MTrP pain in the upper quadrant and three studied pain in the lower quadrant (lumbopelvic region).[@b35-jpr-10-1933] Meta-analysis of four studies using a placebo as control showed that needling did not appear to be significantly superior to placebo (standardized mean difference \[SMD\] =14.9, 95% CI: −5.81, 33.99).[@b35-jpr-10-1933] The authors concluded that dry needling had a comparable treatment effect as placebo on MTrP pain.[@b35-jpr-10-1933] However, this meta-analysis was conducted based on only four RCTs, and it suffered from limited sample size, poor quality, and substantial heterogeneity in the data pool, which precluded making definitive conclusions.[@b35-jpr-10-1933] Cotchett et al[@b36-jpr-10-1933] performed a systematic review of three quasi-experimental trials to assess the effectiveness of dry needling and/or injections for MTrPs associated with plantar heel pain. In that study, two trials found a reduction in pain for the use of MTrP dry needling combined with acupuncture, and the third trial observed a reduction in pain using 1% lidocaine injections in combination with physical therapy.[@b36-jpr-10-1933] However, because of the substantial heterogeneity and poor methodological quality of the three trials, the authors did not conduct the meta-analysis.[@b36-jpr-10-1933] In an updated systematic review conducted by Tough and White,[@b37-jpr-10-1933] the authors included six RCTs to investigate the effectiveness of acupuncture/dry needling for MTrP pain. In the four RCTs that were used to undertake a meta-analysis, the population group varied from patients with upper trapezius pain and young athletes with gluteal MTrP causing hamstring pain on the one hand to elderly patients with chronic neck pain and chronic low back pain on the other.[@b37-jpr-10-1933] Meta-analysis of the four RCTs showed that needling was statistically superior to placebo in reducing pain (WMD =16.67, 95% CI: 3.23, 30.11).[@b37-jpr-10-1933] However, the authors suggested that their results should be interpreted with caution since marked heterogeneity (*I*^2^=82.6%) was observed among the studies.[@b37-jpr-10-1933]

Our meta-analysis showed that MTrP dry needling had beneficial effect in pain relief. Our results were consistent with the findings of several published studies. Tillu and Gupta[@b26-jpr-10-1933] evaluated the effect of a 4-week period of acupuncture, followed by 2 weeks of acupuncture combined with MTrP needling of the calf and heel regions.[@b26-jpr-10-1933] Their result showed significant reduction in plantar heel pain, as measured in a VAS.[@b26-jpr-10-1933] Perez-Millan and Foster[@b38-jpr-10-1933] investigated a 6-week period of MTrP needling combined with electroacupuncture of the heel and arch, and they found significant improvement in the plantar heel pain. Cotchett et al[@b28-jpr-10-1933] performed a parallel-group, participant-blinded, RCT to evaluate the effectiveness of dry needling for plantar heel pain. During the 6-week treatment, patients received the real or sham MTrP dry needling. They found that real dry needling was more effective than sham dry needling in pain reduction (adjusted mean difference, VAS pain score =−14.4, 95% CI: −23.5, −5.2), but real dry needling also resulted in a greater frequency of minor transitory adverse events than sham dry needling.[@b28-jpr-10-1933]

The effect of MTrP needling could be explained by several mechanisms, although these mechanisms are largely derived from research involving traditional acupuncture. It has been proposed that dry needling could reduce the pain by affecting the biochemical environment and local blood flow surrounding an MTrP and, ultimately, the nervous system.[@b28-jpr-10-1933] Shah et al[@b14-jpr-10-1933] reported that the concentration of substance P and calcitonin gene-related peptide surrounding an MTrP was significantly decreased following the dry needling intervention. In an animal model, Hsieh et al[@b39-jpr-10-1933] found that a single dry needling procedure in the biceps femoris muscle significantly reduced the levels of substance P and increased the β-endorphin level in local tissue and serum, which indicated a short-term analgesic effect for dry needling. Cagnie et al[@b40-jpr-10-1933] found increased blood flow and oxygen saturation in the immediate vicinity of MTrPs for 15 minutes following a single dry needling intervention of the upper trapezius muscle. The increased blood flow to the region might remove the pain-inducing substances.[@b14-jpr-10-1933]

Although the results of this study suggested that MTrP dry needing significantly reduced the foot pain beneath the heel, the inconvenience brought by it should not be neglected. It was noted from our study that dry needling resulted in minor adverse events (needle site pain or subcutaneous bleeding) and that the incidence of these events was similar to that in the control. In the study conducted by Cotchett et al,[@b28-jpr-10-1933] it was estimated that for every three patients treated with dry needling, one person will experience an immediate adverse event. Patients should be informed about the possibility of these relatively mild and transitory adverse events before the treatment, so that they can weigh the benefits and risks of dry needling.

This meta-analysis has several potential limitations that should be taken into account. First, we acknowledge that some of the included RCTs had a relatively small sample size (N\<50). Small trials are more likely to result in an overestimated treatment effect compared with larger trials. Second, there was substantial heterogeneity among the included studies. However, this should not be surprising given the large variation in the treatment approaches, needling technique, diagnostic criteria for MTrP, and study design. These factors might increase the heterogeneity and have a potential impact on the treatment effect. Third, two of the included studies were classified as being at high risk of bias, which reduced the reliability of the original results.

Conclusion
==========

This meta-analysis indicated that MTrP needling effectively reduced the heel pain due to plantar fasciitis. However, the findings should be interpreted with caution due to the limitations in terms of substantial heterogeneity, poor quality, and small sample size. More large-scale, adequately powered, good-quality placebo-controlled trials are needed to provide more trustworthy evidence in this area.
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![Forest plot showing the effect of MTrP needling on the VAS score.\
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**Note:** Weights are from random-effects analysis.\
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![Forest plot showing the test for publication bias for WMD of the changes in VAS score.\
**Note:** Figure shows Begg's funnel plot with pseudo 95% confidence limits.\
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###### 

Baseline characteristics of patients in the trials included in the meta-analysis

  First author, reference             Country                      Treatment regimen                 No of patients   Male/female patients   Age (mean ± SD, years)   Duration of heel pain (mean ± SD, months)
  ----------------------------------- ---------------------------- --------------------------------- ---------------- ---------------------- ------------------------ -------------------------------------------
  Cotchett MP[@b28-jpr-10-1933]       Australia                    Real trigger point dry needling   41               17/24                  54.4±12.4                13.4±14.1
  Sham trigger point needling         43                           27/16                             57.8±12          13.7±17.3                                       
  Zhang SP[@b29-jpr-10-1933]          People's Republic of China   Acupuncture (PC7)                 28               8/20                   47±2.2                   44.9±8.8
  Acupuncture (LI4)                   25                           6/19                              50±2.0           22.9±8.8                                        
  Eftekharsadat B[@b30-jpr-10-1933]   Iran                         Dry needling                      10               3/7                    50.3±9                   NR
  NR                                  10                           4/6                               50.9±8.9         NR                                              
  Li SM[@b31-jpr-10-1933]             People's Republic of China   Miniscalpel--needle               31               10/19                  54.74±10.16              8.81±2.79
  Steroid injection                   30                           7/25                              56.93±9.25       9.8±2.94                                        
  Kumnerddee M[@b32-jpr-10-1933]      Thailand                     Acupuncture                       15               3/12                   52.4±10.5                15.5±19.4
  Conventional treatment              15                           0/15                              53.8±8           11.7±5.3                                        
  Wang LF[@b33-jpr-10-1933]           People's Republic of China   Warm needling plus                54               32/22                  52.21±5.02               6.04±0.95
  Chinese herb fumigation             54                           31/23                             61.25±7.25       7.36±1.26                                       
  Qian SH[@b34-jpr-10-1933]           People's Republic of China   Warm needling plus                31               14/17                  36--72                   1--36
  Chinese herb fumigation             30                           13/17                             38--69           2--26                                           

**Abbreviation:** NR, not reported.

###### 

GRADE evidence profile

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality assessment                                             No of patients      Effect                                               Quality                                              Importance                                                                                                                                                                                                                       
  -------------------------------------------------------------- ------------------- ---------------------------------------------------- ---------------------------------------------------- ------------------------- ------------------------ --------------------------------------------------------------- ---------- ---------- ------------------------ --------------------------------------------------- ---------- -----------
  **Changes in VAS scores (better indicated by lower values)**                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                

  7                                                              Randomized trials   Serious[a](#tfn2-jpr-10-1933){ref-type="table-fn"}   Serious[b](#tfn3-jpr-10-1933){ref-type="table-fn"}   No serious indirectness   No serious imprecision   Strong association[c](#tfn4-jpr-10-1933){ref-type="table-fn"}   210        207        --                       WMD-15.5 lower\                                     Moderate   Critical
                                                                                                                                                                                                                                                                                                                                                                 (−19.48 higher to −1 1.53 lower)                               

  **Success rate for pain**                                                                                                                                                                                                                                                                                                                                                                                                     

  3                                                              Randomized trials   No serious risk of bias                              Serious[d](#tfn5-jpr-10-1933){ref-type="table-fn"}   No serious indirectness   No serious imprecision   None                                                            85/100\    71/99\     RR 1.15 (0.87--1.51)     108 more per 1,000 (from 93 fewer to 366 more)\     Moderate   Important
                                                                                                                                                                                                                                                                                                                  (85%)\     (71.7%)\                            112 more per 1,000 (from 97 fewer to 38 1 more)                
                                                                                                                                                                                                                                                                                                                  --         74.7%                                                                                              

  **Adverse events**                                                                                                                                                                                                                                                                                                                                                                                                            

  3                                                              Randomized trials   Serious[e](#tfn6-jpr-10-1933){ref-type="table-fn"}   Serious[f](#tfn7-jpr-10-1933){ref-type="table-fn"}   No serious indirectness   No serious imprecision   None                                                            83/262\    18/140\    RR 1.89 (0.38 to 9.39)   114 more per 1,000 (from 80 fewer to 1.000 more)\   Low        Important
                                                                                                                                                                                                                                                                                                                  (31.7%)\   (12.9%)\                            356 more per 1,000 (from 248 fewer to 1.000 more)              
                                                                                                                                                                                                                                                                                                                  --         40%                                                                                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Two trials were judged to be at high risk of bias.

Moderate heterogeneity (*I*^2^ =56.8%) was found.

A total of 417 patients were enrolled.

Substantial heterogeneity (*I*^2^=78.0%) was found.

One trial was judged to be at high risk of bias.

Substantial heterogeneity (*I*^2^ =85.0%) was found. '--' indicates no data.

**Abbreviations:** GRADE, Grading of Recommendations Assessment, Development and Evaluation; RR, risk ratio; WMD, weighted mean difference; VAS, visual analog scale.
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